Anticancer candidate substance RX-0201 likely to be commercialized in 2007

Korean health food maker Rexgene Biotech and Maryland-based Rexahn Corporation in the US, said it made a joint research agreement on RX-0201, a promising anticancer substances, on February 6.

Under the agreement, Rexgene Biotech will offer an initial clinical expenditure of $1.5 million to Rexahn Corporation and thereafter, the former will have an exclusive marketing right of RX-0201 in the...